Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of rosiglitazone XR in mild to moderate Alzheimer's disease
2004-000985-12Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rosiglitazone in Alzheimer's disease (AD), sponsored by GSK. Primary endpoint: Frequency of adverse events. Started Aug 2004; status: completed.
02
Drugs
rosiglitazone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2004-000985-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000985-12.